Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Coya Therapeutics, Inc. filings document regulatory and financial disclosures for a clinical-stage biotechnology company developing Treg-enhancing biologics for neurodegenerative disorders. The record includes Form 8-K reports on operating results, corporate updates, clinical and regulatory disclosures for COYA 302, and study results involving low-dose IL-2 and CTLA4-Ig approaches in frontotemporal dementia.
Filings also cover material agreements and milestone payments under the company’s development and license relationship with Dr. Reddy’s Laboratories, board and executive-chairman changes, compensation and separation arrangements, and capital-structure disclosure for Coya’s Nasdaq-listed common stock. These documents provide formal disclosure of governance matters, collaboration economics, clinical-program status, and other material events.
Dr. Reddy's Laboratories reported beneficial ownership of 2,272,727 shares of Coya Therapeutics, Inc. common stock, representing 9.7% of the class. The shares are directly held by Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories SA and Dr. Reddy's Laboratories Limited are disclosed as potentially deemed beneficial owners through the corporate chain.
The filing cites 20,924,456 shares outstanding as of November 10, 2025 and 2,522,727 shares issued and outstanding as of January 29, 2026 in related issuer reports; the ownership table shows sole voting and dispositive power for the 2,272,727 shares.
The Vanguard Group reported beneficial ownership of 899,140 shares of Coya Therapeutics Inc common stock, representing 4.29% of the class as of December 31, 2025. Vanguard has shared voting power over 117,776 shares and shared dispositive power over all 899,140 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s clients, who have rights to dividends and sale proceeds, and no single other person has more than 5% interest in these securities. Vanguard notes an internal realignment on January 12, 2026, after which certain subsidiaries may report beneficial ownership separately while pursuing the same investment strategies.
Coya Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 2,522,727 common shares at $4.40 per share, raising approximately $11.1 million in gross proceeds. The investors are Dr. Reddy’s Labs, contributing $10.0 million, and Greenlight Capital, an existing institutional stockholder, contributing $1.1 million.
The company plans to use the net proceeds to transfer and scale manufacturing of low dose IL‑2 and accelerate manufacturing programs needed for commercial readiness of COYA 302. Management states these funds are expected to support accelerated commercial readiness plans while reiterating cash runway guidance into the second half of 2027 and past the projected topline for the ALSTARS trial.
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Mr. Hirschman reports beneficial ownership of 1,108,171 shares, representing 5.3% of Coya’s common stock, with sole voting and dispositive power over these shares. AIGH Capital Management LLC reports beneficial ownership of 975,404 shares, representing 4.7% of the class, also with sole voting and dispositive power. The filing is made on a passive basis, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coya Therapeutics.
Coya Therapeutics reported that its Chief Financial Officer, David S. Snyder, received a grant of stock options on January 22, 2026. The award covers 140,041 stock options, each giving the right to buy one share of common stock at an exercise price of $4.73 per share.
The options vest in monthly installments over 36 months, as long as the executive continues to serve through each vesting date. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Coya Therapeutics, Inc. reported that Chief Medical Officer Fred Grossman received a grant of stock options to purchase 140,041 shares of common stock at an exercise price of $4.73 per share. The options were awarded at no cash cost at grant and are held directly. Subject to continuous service, the shares underlying the option vest in monthly installments over the next 36 months. If there is a change in control of the company, all unvested options will fully vest and become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended effective November 17, 2022.
Coya Therapeutics, Inc. reported that Executive Chairman Howard Berman received a stock option grant on 01/22/2026. The option gives him the right to buy 15,257 shares of common stock at an exercise price of $4.73 per share.
These options vest in monthly installments over the next 36 months, as long as he remains in continuous service through each vesting date. The filing also states that if there is a change in control of the company, all unvested shares under this option will vest and the option will become immediately exercisable under Coya’s 2021 Equity Incentive Plan, as amended in November 2022.
Coya Therapeutics, Inc. reported a new equity award to its Chief Executive Officer, Swaminathan Arun. On January 22, 2026, he received a stock option covering 293,983 shares of common stock with an exercise price of $4.73 per share.
These options were granted at a price of $0 for the derivative itself and are held directly. The shares underlying the option vest in monthly installments over 36 months, conditioned on continued service. If there is a change in control of Coya Therapeutics, all unvested shares under this option will vest and the option will become immediately exercisable under the company’s 2021 Equity Incentive Plan, as amended and restated effective November 17, 2022.
Coya Therapeutics, Inc. filed a current report describing a stockholder letter that updates its financial position and key clinical milestone timing. The company reported an unaudited cash balance of $46.8 million as of December 31, 2025, and stated it has a projected cash runway into the second half of 2027, indicating it currently expects to fund operations for an extended period. Coya also noted that it expects a topline data readout from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, giving investors a timeframe for when important clinical results may become available.
Coya Therapeutics reported early clinical data from an investigator-initiated, open-label proof-of-concept study using a combination of low-dose IL-2 and CTLA4-Ig in 9 patients with Frontotemporal Dementia over about six months. Patients received subcutaneous CTLA4-Ig plus a 5-day course of low-dose IL-2 every four weeks for a total of 22 weeks of dosing and follow-up.
The treatment was generally well tolerated: the most common side effect was mild injection-site redness in 33.3% of individuals, and no serious adverse events were observed. Measures of regulatory T cell (Treg) activity and markers such as CD25 and FOXP3 showed significant increases as early as two weeks after dosing and remained elevated through week 22.
Cognitive outcomes, measured by Montreal Cognitive Assessment and CDR-FTLD scores, were essentially stable from baseline (MOCA 13.5; CDR-FTLD 4.8) to week 22 (MOCA 14; CDR-FTLD 5.5), suggesting no notable decline in cognitive or functional status over the treatment period in this small group.